Group 1: Company Overview and Financial Performance - Fujian Snowman Group Co., Ltd. was established in 2000, focusing on advanced equipment manufacturing in cold chain logistics, industrial refrigeration, clean energy, and hydrogen power sectors [1] - In the first three quarters of 2025, the company achieved a revenue of CNY 1.631 billion, representing a year-on-year increase of 24.26% [1] Group 2: Controlled Nuclear Fusion Business - The company is involved in the controlled nuclear fusion sector, utilizing helium compressors as core components for large-scale low-temperature systems [1] - The "large-scale low-temperature refrigeration system" project employs the company's "megawatt-level" helium compressor, capable of achieving cooling at -271°C with a cooling capacity of 100 watts [2] - The technology has received national scientific achievement evaluation, reaching an internationally leading level with significant social and economic benefits [2] Group 3: Hydrogen Energy Sector - The company has developed a long-term strategy in the hydrogen fuel cell sector, focusing on core technologies within the supply chain [3] - It has established hydrogen technology R&D institutions in Europe and Japan, working on key components and materials for hydrogen fuel cells [3] - The company is advancing the mass production of hydrogen fuel cells and core components, gradually building a complete industrial ecosystem [3] Group 4: Data Center Business Expansion - The company has entered the data center sector, leveraging its compressor technology to offer a diverse product line, including piston, open-type screw, semi-closed screw, and centrifugal compressors [4] - It has implemented low-charge ammonia refrigeration technology in overseas data centers, providing energy-efficient and environmentally friendly solutions [4] - The company’s subsidiary, Hangzhou Longhua, is involved in major data center refrigeration engineering projects for leading enterprises like China Mobile and Alibaba [4] Group 5: Ice Making Products Development - The company has seen significant growth in its ice-making products, particularly in the industrial construction and ice and snow sectors [5] - Demand in the Middle East for large-scale infrastructure projects is expected to drive rapid growth in the industrial construction sector over the next three to five years [5] - The company's ice-making and snow-making products are utilized in over 30 global ice and snow projects annually, establishing a stable business foundation [5] Group 6: Future Outlook - The company aims to continue expanding application scenarios and strengthening technological advantages while seizing opportunities in national strategies and global trends [5] - It plans to leverage innovative products and comprehensive service capabilities to drive steady business growth [5]

Group 1: Company Overview - The company specializes in the research, production, and sales of IoT intelligent products, focusing on communication, positioning, and AI technologies [1] - It aims to become a global expert in IoT intelligent application solutions, adhering to the mission of "empowering wisdom for a better future" [1] Group 2: Financial Performance - In 2024, the company achieved a revenue of CNY 1.402 billion, a year-on-year increase of 24.85%, and a net profit of CNY 176 million, up by 0.81% [2] - For the first three quarters of 2025, the company reported a revenue of CNY 1.272 billion, a 21.66% increase year-on-year, and a net profit of CNY 180 million, reflecting a 33.95% growth [2] Group 3: Market Outlook - The demand for smart vehicle terminals and smart sleep terminals is expected to continue growing, supported by favorable market conditions [2] - The installation penetration rate of smart vehicle video recorders in the domestic heavy-duty truck sector is currently low, indicating potential growth opportunities [2] Group 4: International Expansion - The company is leveraging the "Belt and Road" initiative to expand its market presence in Africa, Southeast Asia, and Central Asia, while also targeting developed markets in Europe and North America [3] - It has successfully entered the supplier system of an overseas automotive brand, beginning small-scale supply [3] Group 5: Product Diversification - The company has diversified its product offerings across various scenarios, including smart transportation, smart sleep, and mobile payment, with a focus on customer-driven solutions [4] - The smart sleep terminal can track and analyze users' sleep states, adjusting the environment for optimal sleep quality [5] Group 6: Core Competencies - The company's ability to adapt technology to various application scenarios is a key strength, supported by extensive experience in core technologies such as communication, positioning, and AI [4] - The fragmented nature of the IoT market allows the company to customize solutions effectively, enhancing product competitiveness [4] Group 7: Supply Chain Management - Storage chips are primarily used in commercial vehicle monitoring terminals, with their cost impact on the company being relatively low due to existing reserves [6]

Financial Performance - In the first three quarters of 2025, the company achieved operating revenue of CNY 30.654 billion, a year-on-year increase of 2.47% [2] - Net profit attributable to shareholders reached CNY 4.777 billion, exceeding the full-year 2024 figure of CNY 4.749 billion, with a year-on-year growth of 10.41% [2] - Non-recurring net profit was CNY 4.550 billion, surpassing the 2024 full-year figure of CNY 4.523 billion, reflecting a year-on-year increase of 6.68% [2] - The weighted average return on equity was 11.92%, up by 1.10 percentage points year-on-year [2] - Operating cash flow net amount reached CNY 4.456 billion, a year-on-year increase of 9.40% [2] - As of the end of the period, cash and cash equivalents totaled CNY 8.618 billion, with a debt-to-asset ratio of 25.36% [2] Pharmaceutical Business Development - The pharmaceutical division implemented integrated marketing strategies focusing on various scenarios, achieving over 20% growth in O2O sales [4] - Online sales during the 2025 "618" shopping festival saw significant improvements, with 48.45 million visitors and a GMV of CNY 254 million [4] - Clinical research on products like Yunnan Baiyao (powder) and capsules for diabetes foot and bone pain showed steady progress [4] Health Products Performance - The health products division maintained its leading market share in toothpaste, while the brand "Yangyuanqing" ranked first in Tmall for anti-hair loss shampoo during the 2025 "618" period [6] Acquisition and Integration Strategy - The acquisition of Juyitang aims to enhance the company's capabilities in the traditional Chinese medicine sector, with a production capacity of 25,000 tons for herbal pieces and 1,500 tons for formula granules [7] - Juyitang's established online sales channels and large B-end customer base are expected to provide strategic synergies and improve operational efficiency [7] Research and Development Pipeline - The company is focusing on secondary innovation and rapid drug development, with 16 major traditional Chinese medicine projects and 37 ongoing projects [8] - Key projects include the completion of Phase II clinical trials for Sanqi tablets and the initiation of Phase III trials for various products [8] - Long-term projects include the launch of clinical trials for innovative drugs and monoclonal antibody projects [8]

Group 1: Investor Relations Activity - The meeting was categorized as an analyst meeting and included one-on-one communication with various investment firms [2] - Participants included representatives from multiple investment firms and individual investors [2] Group 2: Meeting Details - The meeting took place on November 12, 2025, at the company's headquarters [2] - The main purpose of the meeting was to understand the company's production and operational status [2] Group 3: Attendees - Notable attendees included representatives from Jiangxi Zhifeng Consulting, Guangdong Zhenyuan Private Equity Fund, and other investment entities [2] - Company representatives included Zhang Yu, Yang Kexin, and Yu Yang from the investor relations management team [2]

Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [2] - Participants included representatives from various investment firms and individual investors [2] - The meeting took place on December 10, 2025, at the company's headquarters [2] Group 2: Purpose of the Meeting - The main objective was to understand the company's production and operational status [2]

Group 1: Health Products Business Performance - In the first half of 2025, the health products segment achieved revenue of 3.442 billion CNY, a year-on-year growth of 9.46% [2] - The segment focuses on a full-channel operation strategy, enhancing offline distribution and increasing online promotion efforts [2] - Key products include oral care toothpaste, which maintains a leading position, and hair care brand Yangyuanqing, which continues to grow driven by online sales [2][4] Group 2: Pharmaceutical Business Performance - The pharmaceutical segment reported a main business revenue of 4.751 billion CNY in the first half of 2025, with a year-on-year increase of 10.8% [5] - Sales of Yunnan Baiyao aerosol exceeded 1.453 billion CNY, showing a significant growth of over 20.9% [5] - Other traditional Chinese medicine products also saw notable growth, with sales of Qianling Jianpi Granules surpassing 100 million CNY and Pudilan Anti-inflammatory Tablets nearing 100 million CNY [5] Group 3: Traditional Chinese Medicine Resource Business - The traditional Chinese medicine resource segment generated external revenue of 914 million CNY in the first half of 2025, reflecting a year-on-year growth of approximately 6.3% [6] - The segment implements a "six unifications" operational model to enhance the traditional Chinese medicine industry chain [7] Group 4: R&D and Innovation Progress - The company emphasizes innovation-driven development, focusing on both traditional Chinese medicine and innovative drugs [8] - In the first half of 2025, the company initiated phase III clinical trials for the prostate cancer diagnostic nuclear drug project INR101, with 60 subjects enrolled [9] - The innovative drug project INR102 for prostate cancer treatment received clinical trial approval, and phase I trials have commenced [9] Group 5: Dividend Distribution - For the 2024 fiscal year, the company distributed a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.164 billion CNY [10] - The total cash dividend for 2024, including special dividends, amounted to 4.279 billion CNY, representing 90.09% of the net profit attributable to shareholders [10] - In the first half of 2025, the company distributed a cash dividend of 10.19 CNY per 10 shares, totaling 1.818 billion CNY, which accounted for 50.05% of the net profit for that period [10]

证券代码：301632 证券简称：广东建科 广东省建筑科学研究院集团股份有限公司 投资者关系活动记录表 答：公司重视科技创新和数字化转型，近三年主营业务研发费 用率呈现逐年上升趋势，主要投入于行业战略性、前沿性领域的研 发，绿色低碳科技研究等方面的研究。截至 2025 年 6 月 30 日，公 编号：2025-021 投资者关系 活动类别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 ☑ 现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 人员姓名 广州泽恩投资 曹盈盈 松山创业投资 吴德有 深圳中天汇富基金管理有限公司 何佑胜 广东金豆子 马杰辉 深圳诚和昌私募基金投资有限公司 戴九侯 中金资本 刘弦 灏达投资 资香莲 乐盈(珠海)私募证券投资公司 鲍传广 东北证券 吴源恒 广州市摩星岭控股有限公司 董佳宁 广州南杰利私募基金 林小峰 广州瑞民基金 罗小明 广新基金 赖增强 中大情私募基金管理有限公司 刘剑荣 广东凯鼎投资有限公司 甄义勇 华福证券 王二鑫 润生投资 汪江涛 乐盈投资 李俊 时间 2025 年 12 月 12 日（星期五）14:00-16:30 ...

Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [2] - Participants included individual investors: Huang Kaiwei, Li Minggui, Chen Jiahe, Guo Hao, and Cui Weigang [2] - The meeting took place on December 10, 2025, at the Group's headquarters [2] Group 2: Company Overview - The main purpose of the investor relations activity was to understand the company's production and operational status [2] - Company representatives included Zhang Yu, Yang Kexin, and Yu Yang from the investor relations management team [2]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical business group achieved a main business revenue of 4.751 billion yuan, a year-on-year increase of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded 1.453 billion yuan, with a significant year-on-year growth of over 20.9% [2] - Other core products, including Yunnan Baiyao plaster and capsules, also saw notable growth, contributing to the overall revenue increase [2] - Plant-based products, such as Qixue Kang oral liquid, reached sales of 202 million yuan, with a year-on-year growth of approximately 116.2% [2] Group 2: Health Product Channel Development - The company has established a comprehensive national sales team for health products, maintaining a leading market share in Yunnan Baiyao toothpaste [4] - Continuous optimization of the entire channel has strengthened traditional offline advantages while also focusing on emerging retail formats like instant retail and community group buying [4] Group 3: Traditional Chinese Medicine Cultivation Achievements - The company has implemented a precise research and transformation model for seed innovation, achieving coverage of ten major Yunnan medicinal sources [5] - The area of high-quality seed promotion has reached 90% of the annual target, with significant progress in the construction of "Yun Medicine Seed Valley" [5] - Over 7,000 acres of GAP management have been added for various medicinal herbs, integrating low-altitude economy and IoT technology [5] Group 4: Online Sales Performance - The pharmaceutical business group has expanded its online market, with O2O sales increasing by over 20% year-on-year [6] - During the 2025 "618" shopping festival, the company achieved a GMV of 254 million yuan through e-commerce platforms, attracting 48.45 million visitors [7] - Yunnan Baiyao toothpaste maintained the top market share in the domestic channel, while Yangyuan Qing ranked first in Tmall for anti-hair loss shampoo [7] Group 5: Nuclear Medicine Research Progress - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 60 subjects enrolled [8] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with Phase I trials underway and 12 patients enrolled [8]

Funding and Investment Projects - The company plans to invest ¥68,766.42 million in the "Dingjie Intelligent Ecosystem Empowerment Platform Project," which includes the establishment of a research and training base and platform project development [2] - An additional ¥14,000 million will be allocated to supplement working capital to support daily operations and business development [2] Relationship with Existing Business - The platform project development is an upgrade based on the company's existing platform research, enhancing product functionality and application areas [3] - The training base will serve as a research facility and a center for client training and demonstrations, aiding in customer maintenance and expansion [3] Industry Development and Policy Support - The industrial sector is experiencing strong policy support for AI applications, as highlighted by the Ministry of Industry and Information Technology's initiative to implement "Artificial Intelligence + Manufacturing" actions [3] - This initiative aims to enhance industrial production efficiency, optimize processes, and promote the integration of industrial software with AI [3] Management Efficiency Measures - The company is enhancing internal management by leveraging AI technology to optimize operations, research, delivery, and marketing processes, thereby improving overall operational efficiency [3] Future Development Strategy - The company will adhere to the "Intelligent +" strategy, focusing on innovating productivity through data and intelligent technology [3] - Plans include transitioning to a platform ecosystem model, further developing the Dingjie Athena platform and new applications to provide high-value tools and environments for ISV partners and clients [3]